Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TERT | O14746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7274342 | 0.85 | MAP4K4 (0.45) | ALDH1A1CYP3A4CYP2A6 | |
| SCHEMBL4418842 | 0.81 | KMT2A (0.47) | KMT2ASLC6A2SLC6A4SLC6A3MEN1 | |
| SCHEMBL2318636 | 0.80 | USP2 (0.44) | SLC6A2SLC6A4SLC6A3ALDH1A1KDM4E | |
| SCHEMBL124070 | 0.78 | AR (0.47) | KMT2AMEN1ALDH1A1KDM4ECYP1A2 | |
| SCHEMBL3642709 | 0.76 | KMT2A (0.48) | KMT2AMEN1ALDH1A1GAACYP1A2 | |
| SCHEMBL18599493 | 0.76 | AR (0.46) | KMT2ASLC6A2SLC6A4SLC6A3MEN1 | |
| SCHEMBL28167411 | 0.76 | KMT2A (0.42) | KMT2AMEN1ALDH1A1GAACYP1A2 | |
| SCHEMBL14685626 | 0.76 | KMT2A (0.44) | KMT2ASLC6A2SLC6A4SLC6A3MEN1 | |
| SCHEMBL20997528 | 0.76 | KMT2A (0.38) | KMT2ASLC6A4SLC6A3MEN1ALDH1A1 | |
| SCHEMBL98131 | 0.74 | TTR (0.48) | ALDH1A1KDM4EGAACYP2A6LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040516-B2 | Uracil derivative and use thereof for medical purposes | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-9040516-B2 | Uracil derivative and use thereof for medical purposes | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-20140179670-A1 | URACIL DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-06-26 | — | — | US | disclosed |
| US-20140179670-A1 | URACIL DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-06-26 | — | — | US | disclosed |
| EP-2740728-A1 | URACIL DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2014-06-11 | — | — | EP | disclosed |
| WO-2013018804-A1 | URACIL DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | 大日本住友製薬株式会社 (JP) | 2013-02-07 | — | — | WO | disclosed |
| US-5852192-A | Cyclic urea derivatives, pharmaceutical compositions containing these compounds and processes for preparing them | DR. KARL THOMAE GMBH (DE) | 1998-12-22 | — | — | US | disclosed |
| US-5650424-A | ANTIAGGLOMERANTS USING IMIDAZOLIDINDIONES | DR. KARL THOMAE GMBH (DE) | 1997-07-22 | — | — | US | disclosed |
| EP-0503548-B1 | Cyclic urea derivatives, medicaments contaning them and process for their preparation | THOMAE GMBH DR K (DE) | 1997-06-04 | — | — | EP | disclosed |
| US-5478942-A | Antiinflammatory agents, antiagglomerants | KARL THOMAE GMBH (DE) | 1995-12-26 | — | — | US | disclosed |
| US-5276049-A | Treatment of thrombosis | DR. KARL THOMAE GMBH (DE) | 1994-01-04 | — | — | US | disclosed |
| EP-0503548-A1 | Cyclic urea derivatives, medicaments contaning them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1992-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179670-A1 | URACIL DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | URB2, ELANE, NUDT1 | KMT2A 4525/4885SLC6A2 1450/4885SLC6A4 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.